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et al., 2006], and as such microarrays have become the 
first tier diagnostic tool to investigate the genetic basis of 
ID and/or learning disabilities. The introduction of mo-
lecular karyotyping has also led to the identification of 
several new microdeletion and -duplication syndromes 
and also of new genes implicated in ID [Raymond, 2010; 
Vissers and Stankiewicz, 2012; Weise et al., 2012]. Besides 
recurrent deletion and duplication events, rarer copy 
number variations (CNVs) have also been described in 
ID [Koolen et al., 2008; Mikhail et al., 2011].
 In this paper, we present a child with ID and dysmor-
phic features with a de novo deletion in chromosome 
band 2q12.1 affecting only 2 genes:  POU3F3 (OMIM 
602480) and  MRPS9  (OMIM 611975).
 We propose the  POU3F3 gene as a candidate gene for 
ID.
 Case Report 
 The proband is the third child from healthy, nonconsanguine-
ous parents. The family history is not contributory. The boy was 
born at full term with a birth weight of 3,140 g. No feeding prob-
lems were observed.
 Upon physical examination, mild dysmorphic features were 
noted, with a flat nose, prominent ears and eyebrows, mild hyper-
telorism, low anterior hairline, and ogival palate. Blood analysis 
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 Abstract 
 We describe a boy presenting with intellectual disability and 
dysmorphic features in whom a cryptic microdeletion in 
chromosome band 2q12.1 was identified with array CGH. 
The deletion results in a loss of the  POU3F3 and  MRPS9 genes. 
In this paper, we discuss the possible role of POU3F3 haplo-
insufficiency in relation to the boy’s phenotype. 
 © 2013 S. Karger AG, Basel 
 Introduction
Intellectual disability (ID) has a prevalence of about 
1–3% in the general population and is a major health care 
problem. There is a strong genetic etiology for this condi-
tion since in around 28% of patients with ID [Stevenson 
et al., 2003], a genetic aberration can be identified. Until 
now, approximately 450 genes have been described to be 
implicated in ID, but it is estimated that many more need 
to be discovered [Regan and Willatt, 2010].
 The advent of genomic microarrays has led to a strong 
improvement in diagnostic yield in ID patients [Menten 
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with metabolic screening and MRI of the brain showed no abnor-
malities, and EEG revealed no epileptiform alterations.
 The boy presented at the age of 20 months with a mild motor 
delay and ID. He was not able to walk independently nor to pro-
duce any words. The boy showed hypotonia with excessive drool-
ing, normal deep tendon reflexes and joint hyperlaxity. He had an 
average weight and length and a relative small head circumference 
(10th percentile). At the age of 22 months, he had a motor devel-
opmental age of 13 months and a cognitive level of 18 months. 
When he was 2 years old, he could walk but with some rigidity, and 
he lacked good postural responses. Multidisciplinary reassessment 
at the age of 3 years showed a cognitive level of 27 months, a de-
velopmental coordination disorder and a language impairment 
with mainly weak semantics. There were no behavioral problems 
nor social disturbances noted.
 Materials and Methods 
 Informed consent was obtained from the parents, and pater-
nity was evaluated.
 Conventional karyotyping was performed with G-banding by 
standard procedures on short-term lymphocyte cultures. For ar-
ray CGH analysis, DNA was isolated from total blood using the 
QIAamp DNA Blood Mini Kit (Qiagen, Venlo, The Nether-
lands) according to the manufacturer’s instructions. Copy num-
ber profiling was performed on 180K oligonucleotide arrays (Ag-
ilent Technologies, Diegem, Belgium) according to the manufac-
turer’s instructions with minor modifications as described 
[Buysse et al., 2009]. CNV evaluation was performed using the 
in-house developed software tool arrayCGHbase [Menten et al., 
2005].
 The deletion was confirmed by FISH with probes RP11-762O15 
and RP11-574D15 using standard procedures.
 Results 
 Chromosome analysis revealed a normal male karyo-
type: 46,XY.
 Subsequently, array CGH analysis revealed the pres-
ence of 3 CNVs: a de novo deletion in chromosome band 
2q12.1, a maternally inherited triplication in 2q24.2 and 
a maternally inherited deletion in 7q21.11. The inherited 
triplication and deletion were considered as benign 
events, since they contained no known genes and were 
inherited from a healthy parent.
 The karyotype is thus 46,XY.arr[hg19] 2q21.1
(105,337,224–105,696,461)×1 dn.
 The de novo  deletion in 2q12.1 spans 360 kb and con-
tains 2 known genes,  POU3F3 and  MRPS9  ( fig. 1 ). Con-
sultation of the Database of Genomic Variants (http://
dgv.tcag.ca/dgv/app/home) did not reveal this region as a 
benign copy variable region.
 FISH analysis confirmed the deletion in the patient 
( fig. 2 ).
 Fig. 1. Array CGH detail of the proband’s chromosome band 2q12.1, showing the deletion of  POU3F3  and  MRPS9 . 
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 Discussion 
 This report describes a patient with ID and dysmor-
phic features carrying a de novo 360-kb deletion in chro-
mosome band 2q12.1. The deletion results in a loss of 
both the  POU3F3 and  MRPS9  gene.
 POU3F3 is a member of the class III POU family of 
transcription factors which are expressed in the central 
nervous system. These proteins are characterized by the 
presence of a POU domain which recognizes and binds 
an octamer sequence in promoter regions by which they 
can regulate the transcription of target genes [Hara et al., 
1992; Schonemann et al., 1998]. The POU domain pro-
teins play essential roles, not only in the development of 
highly specialized tissues, such as complex neuronal sys-
tems, but also in more general cellular processes [Philips 
and Luisi, 2000; Andersen and Rosenfeld, 2001].
 POU3F3 is a proneural factor that, together with 
ASCL1,  plays an essential role in the activation of  DLL1 
and other neuronal genes, and as such it is very important 
in neurogenesis [Castro et al., 2006].
 Besides this, POU3F3 is also a transactivator of SOX11, 
meaning that these 2 transcription factors work together 
to exert their function [Kuhlbrodt et al., 1998; Kim et al., 
2008]. It has been established that SOX11 is an essential 
actor in normal development of the nervous system 
[Jankowski et al., 2009; Penzo-Méndez, 2010; Mu et al., 
2012]. Interestingly, a patient with ID, dysmorphic fea-
tures and autism carrying a deletion of the  SOX11 gene 
has been reported [Lo-Castro et al., 2009].
 Pou3f3 is important in neuronal development as 
shown in Pou3f3 deficient mice, which present with se-
vere brain deformities [McEvilly et al., 2002; Sugitani et 
al., 2002]. Furthermore, Pou3f3 and Pou3f2 are essential 
for the normal migration of neurons to the cortex [Wolf 
et al., 2009].
 Besides  POU3F3,  the deletion in our patient also spans 
 MRPS9 , a gene that encodes a mitochondrial ribosomal 
protein. MRPS9 is one of more than 70 protein compo-
nents of mitochondrial ribosomes that are encoded by the 
nuclear genome [Rötig, 2011]. Although these genes play 
an important role in mitochondrial functioning, and mu-
tations in some of the family members have been de-
scribed in relation to human diseases, these disorders all 
show an autosomal recessive inheritance pattern and are 
indicative for mitochondrial diseases.
 Deletions in chromosome band 2q12.1 and of  POU3F3 
in particular appear to be rare. This is the first report de-
scribing a patient with a cryptic deletion in chromosome 
band 2q12.1. A large deletion of 2q12q14 in a neonate 
with severe multiple malformations has been reported 
[Antich et al., 1983], but comparison of our case with this 
one is not useful due to the large difference in the deletion 
size.
 The deletion of  POU3F3 in a patient with developmen-
tal delay further emphasizes the role of this gene in neu-
rodevelopment and ID. Additional patients and further 
phenotype-genotype studies are however warranted to 
support this hypothesis.
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 Fig. 2. Confirmation of the deletion by FISH in an interphase nu-
cleus (upper left) and a metaphase nucleus: the RP11-574D15 
probe (spectrum green, white arrow) shows only one signal in the 
normal chromosome 2 (2q12.1 locus). The 2q telomeric probe 
(spectrum orange, Abbott Molecular, Ottignies, Belgium) shows 2 
normal signals (2 split signals in interphase nucleus). 
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